Dianthus Therapeutics DNTH Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 29.3×+13.3× | 13.3×-1.9× | 17.3×-1.0× | 13.1×-23.3× | 16×-26.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Valuation | ||||||
| Market capitalization | $4.44B+662% | $1.77B+174% | $1.57B+67.1% | $583.38M-34.1% | $582.75M-24.3% | |
| Price / book | 3.7×+1.9× | 3.6×+1.8× | 2.9×+0.1× | 1.9×-0.5× | 1.8×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Dianthus Therapeutics's ratios come from?
- Every ratio is computed from Dianthus Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
